Profiling the gut and oral microbiota of hormone-receptor positive, HER2-negative metastatic breast cancer patients receiving pembrolizumab and eribulin (2024)

First Author: Robinson S

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.21203/rs.3.rs-3787741/v1

Publication URI: http://dx.doi.org/10.21203/rs.3.rs-3787741/v1

Type: Preprint